Here are the 8-K filings from Vir Biotechnology, Inc. (VIR) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An 8-K covers material events a company has to report between its quarterly reports, so if you follow VIR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VIR filings page.
Vir Biotechnology, Inc. reported that its Phase 3 ECLIPSE 1 trial met its primary and key secondary endpoints for elebsiran plus tobevibart in adults with chronic hepatitis delta. The primary endpoint response was 44% at Week 48, defined as undetectable HDV RNA plus ALT normalization, versus 0% in the delayed-treatment group at Week 12 (p<0.0001). The key secondary undetectable-virus response was 79% at Week 48 versus 0% in the delayed-treatment group. ECLIPSE 1 randomized 124 patients 2:1. One Grade 3 treatment-related neutrophil-count decrease resolved in 15 days; there were no treatment interruptions or discontinuations.
In Phase 2 SOLSTICE, 28 of 28 patients completing 96 weeks of combination therapy had undetectable viremia, and 89% (24 of 27) with paired liver-stiffness measures had improved or stable readings. In an exploratory treatment-discontinuation analysis, all 10 patients achieved SVR12; among those with later follow-up, 7 achieved SVR24 and 1 achieved SVR48. These first-10-patient data are preliminary and interim, follow-up is ongoing and incomplete, and the company said they do not establish a sustained treatment-free response or cure. The Phase 2 regimen had no study drug-related discontinuations or serious adverse events.
Vir Biotechnology, Inc. reported a third-quarter 2026 net loss of $96.3 million, compared with $163.1 million a year earlier, or $0.57 per share versus $1.17. Research and development expense was $80.0 million versus $151.5 million, primarily reflecting a non-recurring $75.0 million milestone expense in 2025 and collaboration cost recoveries in 2026; higher manufacturing costs partly offset the decrease.
As of September 30, 2026, cash, cash equivalents and investments were approximately $901.3 million, excluding $90 million in upfront consideration from Gilead, and had decreased by $106.5 million during the quarter. Vir expects its cash, cash equivalents and investments to fund operations into the second half of 2028. It received $90 million in consideration under its Gilead collaboration: $65 million upfront and a $25 million equity investment at a 30% premium. Vir is eligible for up to $45 million in near-term preclinical milestones and has potential to receive up to $1.74 billion in development, regulatory and commercial milestones, plus tiered royalties. ECLIPSE 1 topline data are expected in the fourth quarter of 2026; ECLIPSE 2 and 3 topline data are expected in the first quarter of 2027. VIR-5500 received FDA Fast Track designation, achieved proof of concept, and is expected to advance to multiple pivotal trials beginning in 2027.
Vir Biotechnology, Inc. (VIR) expanded its board from eight to nine members and appointed Suzanne Topalian, M.D., as a Class III director, effective October 27, 2026. Topalian will serve until the company’s 2028 annual meeting of stockholders and join the Science and Technology Committee. The company said she was not selected under an arrangement or understanding with any person and that no related-party transactions with her were subject to disclosure. In addition to the indemnification provided to directors under its bylaws, Vir entered into its standard form of indemnity agreement with Topalian.
Vir Biotechnology, Inc. (VIR) entered a global collaboration with Gilead Sciences on October 9, 2026, to discover and engineer three PRO-XTEN® dual-masked T-cell engager development candidates for selected solid tumor-associated antigens. Vir will handle discovery, design and optimization; Gilead will have an exclusive license to nominate and advance candidates and will handle subsequent development, manufacturing and commercialization.
Vir is eligible for up to $135 million in upfront and near-term preclinical milestone payments: $90 million in upfront consideration, including $65 million cash and a $25 million equity investment, plus up to $45 million in potential near-term milestones. Gilead agreed to purchase 1,765,486 common shares at $14.16 per share, for approximately $25 million, subject to customary closing conditions; the equity investment is at a 30% premium. Vir may also receive up to $1.74 billion in further development, regulatory and commercial milestones, plus tiered high single-digit to low double-digit royalties on net sales.
Vir Biotechnology, Inc. (VIR) said the FDA granted Fast Track designation to VIR-5500, a PSMA-targeted PRO-XTEN® dual-masked T-cell engager, for late-line metastatic castration-resistant prostate cancer (mCRPC). The candidate is being co-developed with Astellas Pharma Inc. through a global strategic collaboration. Fast Track is intended to facilitate and expedite development and review of drugs for serious conditions that fill an unmet need.
VIR-5500 is being evaluated in a Phase 1 study across six dose-expansion cohorts, including monotherapy and combination regimens. Vir said Phase 1 data reported earlier this year showed the candidate was generally well tolerated and exhibited promising anti-tumor activity in patients with mCRPC. Phase 3 trials are anticipated to begin in 2027.
Vir Biotechnology, Inc. appointed Aziz Sawaf, MBEE, MBA, CFA, as executive vice president and chief financial officer, effective October 5, 2026. Brent Sabatini will stop serving as interim principal financial officer on that date and continue as senior vice president and chief accounting officer. Sawaf previously served as CFO of Theravance Biopharma since 2023.
Sawaf will receive an annualized base salary of $520,000 and is eligible for an annual bonus targeted at 45% of base salary. His $150,000 sign-on bonus will be paid in two halves: one on or around the effective date and one following its one-year anniversary, subject to continued employment through each payment date. On or around November 15, 2026, Vir has agreed to grant him an option for 150,000 shares and 75,000 restricted stock units. Both awards vest over four years, subject to continued employment; the option’s exercise price will equal fair market value on the grant date.
Vir Biotechnology, Inc. reported second quarter 2026 results highlighted by $238.9 million in total revenues, primarily license and collaboration revenue from a $240.0 million upfront payment from Astellas, and net income of $80.1 million, or $0.48 per share basic, versus a $111.0 million loss a year earlier.
Cash, cash equivalents and investments were approximately $1.01 billion as of June 30, 2026, after receiving a $75 million equity investment from Astellas and making a $48.0 million pass-through payment to Sanofi; this balance is expected to fund operations into the second half of 2028.
In chronic hepatitis delta, Phase 2 SOLSTICE data showed undetectable HDV RNA in 88% of combination-treated participants at Week 96, with 97% in a last-observation analysis and a generally well tolerated profile. The ECLIPSE registrational program is fully enrolled, with key Phase 3 data expected between late 2026 and early 2027, while the Astellas collaboration advances VIR-5500 and other PRO-XTEN T-cell engagers through multiple Phase 1 dose-expansion cohorts.
Vir Biotechnology, Inc. reports that Executive Vice President and Chief Financial Officer Jason O’Byrne informed the company on July 20, 2026 that he will step down from his role effective August 3, 2026 to pursue another opportunity. The company states that his resignation is not due to any disagreement regarding operations, policies, or practices, and it has begun a search for a permanent successor.
On July 23, 2026, the Board appointed Brent Sabatini, CPA, MBA, currently Senior Vice President and Chief Accounting Officer, as interim principal financial officer, effective August 3, 2026. Sabatini, 52, has served as Vir’s Senior Vice President and Chief Accounting Officer since February 2023 and principal accounting officer since October 2024, and previously held finance leadership roles at Capsida Biotherapeutics and Amgen. He has no reportable related-party transactions, no special arrangements relating to his selection, no family relationships with directors or executives, and will receive no additional compensation for the interim role.
Vir Biotechnology, Inc. announced that its Board of Directors increased in size from seven to eight members and appointed Timothy Coughlin, CPA, as a new Class III director effective June 9, 2026. He will serve on the Board until the company’s 2028 annual meeting of stockholders.
Coughlin was also appointed as Chair of the Audit Committee, giving him a key oversight role in the company’s financial reporting. He was not selected pursuant to any arrangement with another person, and the company reports no related party transactions requiring disclosure.
As a non-employee director, Coughlin will receive standard cash and equity compensation under Vir’s non-employee director compensation policy. On his appointment date, he received stock option and restricted stock unit awards under the company’s 2019 Equity Incentive Plan, and he entered into Vir’s standard indemnity agreement for directors.
Vir Biotechnology, Inc. reported governance updates and voting results from its 2026 Annual Meeting of Stockholders. Director Saira Ramasastry will step down from the Board and as Audit Committee Chair effective May 26, 2026, citing a business conflict and no disagreement with the company. Robert More was appointed Audit Committee Chair and the Board size was reduced from eight to seven members. Stockholders elected three Class I directors to serve until the 2029 annual meeting, approved on an advisory basis the compensation of named executive officers, and ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Vir Biotechnology, Inc. reported a first quarter 2026 net loss of $125.7 million, or $0.85 per share, compared with a $121.0 million loss a year earlier. The company ended March 31, 2026 with $809.3 million in cash, cash equivalents and investments and completed a follow-on equity offering raising $172.5 million in gross proceeds.
Vir highlighted positive Phase 2 SOLSTICE data in chronic hepatitis delta, continued progress in its ECLIPSE registrational program, and advancement of its PRO-XTEN® dual-masked T-cell engager oncology pipeline, including the Astellas collaboration on VIR-5500 and dosing of the first patient in Phase 1 dose-expansion cohorts. Based on current plans and including expected Astellas proceeds, Vir now expects its cash resources to fund operations into the second half of 2028.
Vir Biotechnology, Inc. reported a leadership change in its medical organization. Executive Vice President and Chief Medical Officer Mark Eisner, MD, MPH has informed the company that he will step down from his role, effective April 24, 2026. The company has begun a search for a successor to oversee its clinical and medical strategy.
Vir Biotechnology, Inc. has expanded the role of its Chief Executive Officer, Marianne De Backer, M.Sc., Ph.D., MBA, appointing her to the additional position of President effective March 4, 2026. She will now serve as CEO, principal executive officer, and President.
The company notes there are no arrangements or understandings with any other person related to her appointment, no family relationships with any director or executive officer, and no transactions involving her that require related-party disclosure. Biographical details are incorporated by reference from Vir’s April 17, 2025 proxy statement.
Vir Biotechnology, Inc. completed a public offering of common stock to raise new capital. The company sold 17,647,059 shares at $8.50 per share under an underwriting agreement with Goldman Sachs & Co. LLC, Leerink Partners LLC, Evercore Group L.L.C., and Barclays Capital Inc.
The underwriters fully exercised a 30-day option to buy an additional 2,647,058 shares. As a result, Vir Biotechnology issued a total of 20,294,117 shares of common stock, generating aggregate gross proceeds of approximately $172.5 million before underwriting discounts, commissions, and offering expenses.
Vir Biotechnology, Inc. is offering 17,647,059 shares of common stock at $8.50 per share under an underwriting agreement with Goldman Sachs, Leerink Partners, Evercore and Barclays. The offering is expected to close on February 27, 2026, subject to customary conditions.
The underwriters have a 30-day option to buy up to an additional 2,647,058 shares at the public offering price. Vir Biotechnology expects net proceeds of approximately $141.1 million, or about $162.3 million if the option is fully exercised, after underwriting discounts, commissions and estimated expenses.
Vir Biotechnology entered a global collaboration with Astellas to co-develop and co-commercialize VIR-5500, its PSMA-targeting PRO-XTEN® T‑cell engager for prostate cancer. Vir will receive $335 million in upfront and near-term payments, including $240 million in cash and a $75 million equity investment, plus a $20 million milestone tied to manufacturing tech transfer.
Vir is eligible for up to $1.37 billion in additional milestones and tiered double‑digit ex‑U.S. royalties, while sharing U.S. profits 50/50 if it keeps co-promotion rights. Astellas will buy 7,239,382 Vir shares at $10.36, a 50% premium to the 30‑day VWAP. Updated Phase 1 data for VIR‑5500 in metastatic prostate cancer show no dose‑limiting toxicities, grade ≥3 treatment‑related events in 12% of patients, and in higher-dose cohorts PSA50 responses in 82% of evaluable patients and a 45% objective response rate in RECIST‑evaluable patients.
For 2025, Vir reported revenue of $68.6 million, a net loss of $438.0 million (improved from $522.0 million in 2024), and cash, cash equivalents and investments of $781.6 million as of December 31, 2025. The company expects its cash, including effects of the Astellas deal, to fund operations into the second quarter of 2028.
Vir Biotechnology, Inc. reported that it has issued a press release providing a preliminary estimate of its cash, cash equivalents and investments balance as of December 31, 2025. This figure is unaudited and may change, and the company plans to report its full fourth quarter and full-year 2025 financial results in late February 2026.
The company also plans to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 14, 2026 at 3:45 p.m. PT. The related slide deck is being made available as an exhibit and on the company’s investor website, which will also host a live webcast and a 30-day archive of the presentation.
Vir Biotechnology, Inc. entered a license agreement with Norgine Pharma UK Limited for commercial rights to its tobevibart and elebsiran combination for chronic hepatitis delta in Europe, Australia and New Zealand. Vir will receive an initial EUR 55 million reimbursement of development costs and is eligible for up to EUR 495 million in clinical, regulatory and sales milestones, plus tiered mid-teen to high-twenties percent royalties on net sales, while Norgine will contribute about 25% of go-forward external costs for Vir’s ECLIPSE registrational program.
Vir retained rights to the combination in the United States and most other markets outside the Greater China Territory. The company also highlighted Phase 2 SOLSTICE data in chronic hepatitis delta, where 66% (21/32) of participants on the monthly combination achieved sustained HDV RNA target not detected at Week 48, about 90% (29/32) reached hepatitis B surface antigen levels below 10 IU/mL, and 56% (18/32) achieved ALT normalization by Week 48, with the regimen reported as well-tolerated and no grade 3 or higher treatment-related adverse events or treatment-related discontinuations.
Vir Biotechnology, Inc. furnished its quarterly results via an 8-K on November 5, 2025. The filing states that a press release announcing financial results for the quarter ended September 30, 2025 is attached as Exhibit 99.1 and incorporated by reference.
The company notes the information under Item 2.02 is being furnished and not deemed filed under the Exchange Act, limiting associated Section 18 liabilities. The common stock trades on the Nasdaq Global Select Market under the symbol VIR.
Vir Biotechnology (VIR) filed an 8-K to disclose a material R&D milestone. On 24 Jul 2025 the company dosed the first patient in a Phase 1 trial of VIR-5525, an investigational dual-masked T-cell engager that targets EGFR-expressing tumors. Management reported the event under Item 8.01 and attached the related press release as Exhibit 99.1. No financial results, guidance or partnering details were included.
The dosing signals the formal clinical start of VIR-5525 and expands VIR’s oncology pipeline beyond its infectious-disease franchise. While the filing does not quantify trial size, endpoints or timelines, Phase 1 initiation is typically a prerequisite for value-creating data read-outs and potential future partnerships. Investors should note, however, that first-in-human studies are high-risk and non-revenue-generating at this stage.